Core Viewpoint - China National Nuclear Corporation's subsidiary, Shenzhen Zhongke Haidewei Biotechnology Co., Ltd., has received acceptance for its application of "Injection Boron [B] Falan" from the National Medical Products Administration (NMPA), marking a significant step in the development of innovative cancer treatments in China [1] Group 1: Product Development - The "Injection Boron [10B] Falan" is designed for treating tumors that are resistant to radiotherapy and chemotherapy, including recurrent, refractory, infiltrative, advanced, and locally metastatic cancers, showcasing significant clinical advantages [1] - The treatment requires only 1-2 sessions, has low side effects, and integrates diagnosis and treatment, representing a breakthrough in modern precision oncology [1] Group 2: Industry Impact - The submission of the IND application for the BNCT boron drug signifies a breakthrough in the collaborative research and development of domestic BNCT technology, entering a new phase of clinical transformation [1] - This advancement contributes to the "Healthy China" strategy by injecting new momentum from nuclear technology into precision cancer treatment and offers a "Chinese solution" to global cancer treatment challenges [1]

Core Insights - The 2025 China International Service Trade Fair (CIFTIS) commenced in September in Beijing, featuring a forum on "Innovations in Tumor Treatment and New Trends in Drug Development" as a key academic activity [1] - The forum aims to create a high-end communication platform for policy interpretation, results release, industry connection, and international cooperation in the field of tumor prevention and treatment [1][3] Group 1: Forum Objectives and Themes - The forum is centered around the theme "Gathering Global Wisdom to Build a New Future in Cancer Prevention" and focuses on promoting disease prevention research and accelerating the transformation of scientific achievements [3] - The event emphasizes the importance of collaboration among government, industry, academia, and research institutions to enhance tumor prevention and treatment [3][4] Group 2: Scientific and Technological Innovations - Keynote speakers highlighted that technological innovation is crucial for the development of precision medicine in oncology, integrating multi-omics technologies, gene editing, liquid biopsy, and artificial intelligence [4] - The proportion of innovative drugs in development, such as cell therapy and bispecific antibodies, has reached 39% in China, marking a significant shift from generic to innovative drug development [4] Group 3: Challenges and Solutions in Cancer Treatment - Experts discussed the challenges in cancer prevention, including low HPV vaccination rates and insufficient screening coverage, particularly in remote areas and among young women [5][6] - A new model for cervical cancer prevention and control was presented, focusing on a multi-dimensional approach that includes immunology, protein, and gene strategies [6] Group 4: Collaborative Research Initiatives - The forum witnessed the launch of a strategic cooperation agreement for a research project aimed at establishing a standardized system for clinical applications of tumor biotherapy [6] - The project involves multiple institutions and aims to create technical standards and clinical pathways to facilitate the safe and compliant transformation of cutting-edge technologies in the industry [6]

Group 1 - Fudan University Zhongshan Hospital has developed a bile duct cancer precision testing kit that has received approval from the Shanghai Municipal Drug Administration, achieving an 86% increase in overall detection rate and reducing average testing time from 17.6 days to 5 days [1] - Jianyou Co., Ltd. announced that its liraglutide injection has received FDA approval, which may enhance its competitiveness and brand influence in the international market [2] - Jiangsu Lifeng Biotechnology was fined a total of 37.73 million yuan for falsifying registration documents for medical devices, highlighting the regulatory body's zero-tolerance policy towards fraud [3] Group 2 - Tongrentang reported a 4.12% increase in total operating revenue for 2024, reaching 18.597 billion yuan, but its net profit decreased by 8.54% to 1.526 billion yuan, attributed to rising raw material costs and imbalances in marketing and R&D investments [4]